Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort

Trial Profile

Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Buparlisib (Primary) ; Cabazitaxel
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jan 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 28 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Apr 2014 Planned initiation date changed from 1 Mar 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top